Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial.
Rafael GabrielNisa Boukichou-AbdelkaderAleksandra Gilis-JanuszewskaKonstantinos MakrilakisRicardo Gómez HuelgasZdravko A KamenovBernhard PaulweberIlhan SatmanPredrag DjordjevicAbdullah AlkandariAsimina MitrakouNebojsa LalicJesús EgidoSebastián MasJean Henri CalvetJose Carlos PastorJaana LindströmMarcus LindTania AcostaLuis SilvaJaakko Tuomilehtonull On Behalf Of The E-Predice ConsortiumPublished in: Journal of clinical medicine (2023)
in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.